<DOC>
	<DOCNO>NCT01557569</DOCNO>
	<brief_summary>The purpose study examine ability atomoxetine compare placebo increase time relapse methamphetamine dependent volunteer . Our hypothesis atomoxetine increase time ( ) participant relapse .</brief_summary>
	<brief_title>Clinical Efficacy Atomoxetine Methamphetamine Dependence</brief_title>
	<detailed_description>During study participant spend initial 2-weeks study inpatient facility . This help participant initiate withdrawal . During follow 8-weeks participant come 3-4 visit week . Three visit research assistants one visit therapist order work participant use cognitive behavioral therapy approach . Therapy visit typically schedule day participant come clinic anyways number visit per week typically 3 . During 10-week period investigator collect various measure , include vitals , cognitive assessment , mood assessment , urine drug screen , weekly use report methamphetamine , report symptom side effect . This tell investigator atomoxetine safe participant lapse relapse .</detailed_description>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<criteria>Inclusion Criteria . 1865 year old Seeking treatment METH use METH dependence , assess substance abuse section Structured Clinical Interview DSMIV . At least weekly selfreported METH use precede three month period Women childbearing age must negative pregnancy test , agree adequate contraception prevent pregnancy study , agree monthly pregnancy test , nurse Men must agree use effective mean contraception study . Exclusion Criteria . Suicide attempt within past 12 month either suicidal ideation psychotic symptom past 6 month determine study physician . Current opioid , alcohol sedative physical dependence cocaine dependence Major cardiovascular disorder contraindicates study participation ( e.g. , history myocardial infarction , stroke , congestive heart failure , cardiac arrhythmia , hypertension [ i.e. , &gt; 160 SBP &gt; 100 DBP ] unstable medical condition ( e.g. , untreated bacterial infection ) determine study physician . Schizophrenia bipolar disorder type Present recent use ( within 2 week ) overthecounter prescription drug would expect major interaction atomoxetine ( e.g. , monoamine oxidase inhibitor ( MAOI ) , paroxetine , fluoxetine , quinidine , dopamine , albuterol , Î²2agonists ) Medical contraindication receive atomoxetine ( e.g. , severe hepatic impairment , glaucoma , heart disease , hypertension , seizure disorder , document hypersensitivity atomoxetine ) ; bronchospastic condition , ( 2nd 3rd degree AV block , sick sinus rhythm , severe hepatic impairment , document hypersensitivity atomoxetine ) Liver function test ( i.e. , liver enzymes ) great two time normal level Systolic blood pressure &lt; 90 &gt; 160 mmHg , diastolic blood pressure &lt; 60 &gt; 100 mmHg , sit heart rate &lt; 55 &gt; 100 beats/min blood pressure reading &gt; 140 systolic &gt; 90 diastolic three separate , consecutive occasion . History pheochromocytoma Pregnant nursing female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>methamphetamine</keyword>
	<keyword>addiction</keyword>
	<keyword>relapse</keyword>
	<keyword>atomoxetine</keyword>
</DOC>